{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T08:17:02Z","timestamp":1788250622265,"version":"build-2803163510"},"reference-count":29,"publisher":"Faculty of Pharmacy and Pharmaceutical Sciences, University of Karachi","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,1]]},"abstract":"<jats:p>Background: Congenital Adrenal Hyperplasia (CAH) is a group of disorders characterized by impaired adrenal steroid hormone synthesis, with a wide spectrum of clinical manifestations. The prognosis of CAH depends on factors, such as clinical phenotype, treatment and management. Objectives: To analyze the factors influencing the quality of life in children with CAH. Methods: This retrospective study included 30 CAH patients divided into good prognosis (n=13) and poor prognosis (n=17) groups. Clinical characteristics, genetic mutations, treatment compliance, medication regimens and complications were analyzed by t-tests and logistic regression. Results: The good prognosis group presented better compliance (92.31% vs. 47.06%, P=0.017) and hormonal control (84.62% vs. 35.29%, P=0.01). The prevalence of the salt-wasting (SW) type of CAH was higher in the poor prognosis group (70.59% vs. 23.08%, P=0.038), while the simple virilizing (SV) type was higher in the good prognosis group (53.85% vs. 17.65%). The poor prognosis group received a higher hydrocortisone dose (16\u00b13mg\/m2\/day) compared to the good prognosis group (12\u00b14mg\/m2\/day, P=0.025). Complications such as hypertension (P=0.017), hyperpigmentation (P=0.026) and urinary incontinence (P=0.017) were more prevalent in the poor prognosis group. Conclusion: In children with CAH, the quality of life is significantly affected by treatment compliance, hormonal control, and the presence of complications.<\/jats:p>","DOI":"10.36721\/pjps.2026.39.6.151.1","type":"journal-article","created":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T12:12:05Z","timestamp":1775304725000},"source":"Crossref","is-referenced-by-count":0,"title":["Clinical Characteristics And Factors Affecting Quality Of Life In Children With Congenital Adrenal Hyperplasia"],"prefix":"10.36721","author":[{"given":"Shiyi","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"22735","published-online":{"date-parts":[[2026,3,26]]},"reference":[{"key":"ref0","doi-asserted-by":"crossref","unstructured":"Adriaansen BPH, Schroder MAM, Span PN, Sweep F, van Herwaarden AE and Claahsen-van der Grinten HL (2022). Challenges in treatment of patients with non-classic congenital adrenal hyperplasia. Front Endocrinol, 13: 1064024.","DOI":"10.3389\/fendo.2022.1064024"},{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Auchus R J, Sarafoglou K, Fechner P Y, Vogiatzi M G, Imel E A, Davis S M, Giri N, Sturgeon J, Roberts E, Chan J L and Farber RH (2022). Crinecerfont lowers elevated hormone markers in adults with 21-hydroxylase deficiency congenital adrenal hyperplasia. JCEM, 107(3): 801-812.","DOI":"10.1210\/clinem\/dgab749"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Auer MK, Nordenstrom A, Lajic S and Reisch N (2023). Congenital adrenal hyperplasia. The Lancet, 401(10372): 227-44.","DOI":"10.1016\/S0140-6736(22)01330-7"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Barbot M, Mazzeo P, Lazzara M, Ceccato F and Scaroni C (2022). Metabolic syndrome and cardiovascular morbidity in patients with congenital adrenal hyperplasia. Front Endocrinol, 13: 934675.","DOI":"10.3389\/fendo.2022.934675"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Claahsen-van Der Grinten HL, Speiser P W, Ahmed SF, Arlt W, Auchus R J, Falhammar H, Fluck CE, Guasti L, Huebner A, Kortmann BBM, Krone N, Merke DP, Miller WL, Nordenstrom A, Reisch N, Sandberg DE, Stikkelbroeck NMML, Touraine P, Utari A, Wudy SA and White PC (2022). Congenital adrenal hyperplasia-current insights in pathophysiology, diagnostics and management. Endocr Rev., 43(1): 91-159.","DOI":"10.1210\/endrev\/bnab016"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Claahsen-van der Grinten HL, Stikkelbroeck N, Falhammar H and Reisch N (2021). Management of endocrine disease: Gonadal dysfunction in congenital adrenal hyperplasia. Eur J Endocrinol, 184(3): R85-R97.","DOI":"10.1530\/EJE-20-1093"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Dabas A, Vats P, Sharma R, Singh P, Seth A, Jain V, Batra P, Gupta N, Kumar R, Kabra M, Kapoor S, Yadav S (2020). Management of infants with congenital adrenal hyperplasia. Indian Pediatr., 57(2): 159-64.","DOI":"10.1007\/s13312-020-1735-8"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Daniel R, Yadav J, Kumar R, Malhi P, Sharma A and Dayal D (2021). Health-related quality of life and fatigue perception in children with congenital adrenal hyperplasia: A developing nation perspective. Pediatric endocrinology. Diabetes Metab, 27(4): 266-271.","DOI":"10.5114\/pedm.2021.109269"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"D\u00edaz-Garc\u00eda C, Valverde-Molina J, Mart\u00ednez-Gimeno A, Ant\u00f3n-Pacheco Sanchez JL (2023). Quality of life in children with diseases causing central airway obstruction: Reliability and validity of the TAPQOL questionnaire.  Pediatr Pulm, 58(1): 279-87.","DOI":"10.1002\/ppul.26198"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Dreves B, Reznik Y and Tabarin A (2023). Congenital adrenal hyperplasia: New biomarkers and adult treatments. Ann Endocrinol-Paris, 84(4): 472-80.","DOI":"10.1016\/j.ando.2023.01.008"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Ferreira MJ, Moita R, Canha M, Ferreira S, Costa C, Almeida P, Castedo JL, Carvalho D and Castro-Correia C (2021). Quality of life in children diagnosed with non-classic congenital adrenal hyperplasia. Cureus, 13(10): e18937.","DOI":"10.7759\/cureus.18937"},{"key":"ref11","unstructured":"Fraga NR, Minaeian N and Kim MS (2024). Congenit.\"!K\""},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"evil B, Ahmed SF and Krone NP (2023). Quality of?!., life in children and young people with congenital adrenal hyperplasia-UK nationwide multicenter assessment. JCEM, 109(1): e336-e46.","DOI":"10.1210\/clinem\/dgad405"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Liu Y, Chen M, Liu J, Mao A, Teng Y, Yan H, Zhu H, Li Z, Liang D and Wu L (2022). Comprehensive analysis of congenital adrenal hyperplasia using long-read sequencing. Clin Chem, 68(7): 927-39.","DOI":"10.1093\/clinchem\/hvac046"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Maher JY, Gomez-Lobo V and Merke DP (2023). The management of congenital adrenal hyperplasia during preconception, pregnancy, and postpartum. Rev Endocr Metab Dis, 24(1): 71-83.","DOI":"10.1007\/s11154-022-09770-5"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Mallappa A and Merke DP (2022). Management challenges and therapeutic advances in congenital adrenal hyperplasia. Nat Rev Endocrinol. 18(6): 337-352.","DOI":"10.1038\/s41574-022-00655-w"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Merke DP, Mallappa A, Arlt W, Brac De La Perriere A, Linden Hirschberg A, Juul A, Newell-Price J, Perry C G, Prete A, Rees DA, Reisch N, Stikkelbroeck N, Touraine P, Maltby K, Treasure FP, Porter J and Ross RJ (2021). Modified-release hydrocortisone in congenital adrenal hyperplasia. JCEM, 106(5): e2063-e77.","DOI":"10.1210\/clinem\/dgab051"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Merke DP and Auchus RJ (2020). Congenital adrenal hyperplasia due to 21-hydroxylase deficiency. NEJM, 383(13): 1248-61.","DOI":"10.1056\/NEJMra1909786"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Miller WL and White PC (2022). A brief history of congenital adrenal hyperplasia. Horm Res Paediat. 95(6): 529-545.","DOI":"10.1159\/000526468"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Murphy A, Kearns C, Sugi MD and Sweet DE (2021). Congenital adrenal hyperplasia. Radiographics, 41(4): E105-e6.","DOI":"10.1148\/rg.2021210118"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Musa N, Asem N, Basyony S and Fawaz L (2020). Assessment of health-related quality of life in Egyptian children and adolescents with congenital adrenal hyperplasia. JPEM., 33(2): 295-304.","DOI":"10.1515\/jpem-2019-0345"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Nordenstrom A, Falhammar H and Lajic S (2023). Current and novel treatment strategies in children with congenital adrenal hyperplasia. Horm Res Paediat, 96(6): 560-572.","DOI":"10.1159\/000522260"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Prete A, Auchus RJ and Ross RJ (2021). Clinical advances in the pharmacotherapy of congenital adrenal hyperplasia. Eur J Endocrinol, 186(1): R1-R14.","DOI":"10.1530\/EJE-21-0794"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Raghunandan R, Howard K, Smith S, Killedar A, Cvejic E, Howell M, Petrou S, Lancsar E, Wong G, Craig J and Hayes A (2023). Psychometric evaluation of the PedsQL GCS and CHU9D in Australian children and adolescents with common chronic health conditions. AHHP., 21(6): 949-965.","DOI":"10.1007\/s40258-023-00836-2"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Schr\u00f6der MAM, Claahsen-van der Grinten HL (2022). Novel treatments for congenital adrenal hyperplasia. Rev Endocr Metab Dis, 23(3): 631-45.","DOI":"10.1007\/s11154-022-09717-w"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Shafaay EA, Aldriweesh MA, Aljahdali GL, Babiker A, Alomar AO, Alharbi KM, Aldalaan H, Alenazi A, Alangari AS, Alsagheir A, Adriaansen BPH, Claahsen-van Der Grinten HL and Al Alwan I (2023). The clinical characteristics and quality of life of 248 pediatric and adult patients with congenital adrenal hyperplasia. Front Endocrinol, 14: 1122435.","DOI":"10.3389\/fendo.2023.1122435"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"SL, Krishna Prasad H, Ramjee B, Venugopalan L, Ganapathy N and Paramasamy B (2023). Audit of management of children and adolescents with congenital adrenal hyperplasia as per recent Endocrine Society guidelines. Pediatr Endocrinol Diabetes Metab, 29(1): 10-5.","DOI":"10.5114\/pedm.2022.122547"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Tian Y, Hou L, Xiang S, Tian X and Xu J (2023). Congenital adrenal hyperplasia disorder due to 17 \u03b1-hydroxylase deficiency: A case report. Gynecol Endocrinol, 39(1): 2250001.","DOI":"10.1080\/09513590.2023.2250001"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"White PC (2022). Emerging treatment for congenital adrenal hyperplasia. Curr Opin Endocrinol, 29(3): 271-276.","DOI":"10.1097\/MED.0000000000000723"}],"container-title":["Pakistan Journal of Pharmaceutical Sciences"],"original-title":[],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T07:48:12Z","timestamp":1788248892000},"score":1,"resource":{"primary":{"URL":"https:\/\/pjps.pk\/single-article?id=7750"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,26]]},"references-count":29,"URL":"https:\/\/doi.org\/10.36721\/pjps.2026.39.6.151.1","relation":{},"ISSN":["1011-601X","3105-9686"],"issn-type":[{"value":"1011-601X","type":"print"},{"value":"3105-9686","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,26]]}}}